Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShort-Term Debt repayments
Ratios

Gain Therapeutics (GANX) Other Gross PP&E Adjustments (2020 - 2025)

Gain Therapeutics has reported Other Gross PP&E Adjustments over the past 6 years, most recently at -$251654.0 for Q3 2025.

  • Quarterly results put Other Gross PP&E Adjustments at -$251654.0 for Q3 2025, down 524.3% from a year ago — trailing twelve months through Sep 2025 was -$251654.0 (down 524.3% YoY), and the annual figure for FY2024 was -$256801.0, up 59.84%.
  • Other Gross PP&E Adjustments for Q3 2025 was -$251654.0 at Gain Therapeutics, up from -$279502.0 in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for GANX hit a ceiling of -$40310.0 in Q3 2024 and a floor of -$1.0 million in Q4 2021.
  • Median Other Gross PP&E Adjustments over the past 5 years was -$402978.0 (2023), compared with a mean of -$445550.8.
  • Biggest five-year swings in Other Gross PP&E Adjustments: surged 85.83% in 2024 and later plummeted 524.3% in 2025.
  • Gain Therapeutics' Other Gross PP&E Adjustments stood at -$1.0 million in 2021, then surged by 32.7% to -$686550.0 in 2022, then increased by 6.85% to -$639490.0 in 2023, then skyrocketed by 59.84% to -$256801.0 in 2024, then increased by 2.0% to -$251654.0 in 2025.
  • The last three reported values for Other Gross PP&E Adjustments were -$251654.0 (Q3 2025), -$279502.0 (Q2 2025), and -$220617.0 (Q1 2025) per Business Quant data.